Article Listing - Once again, no proof of added benefit found for Boehringer/Lilly's Trajenta by Germany's IQWiG

FUTURE PRODUCTS FROM GENETICS INSTITUTE

6 April 1992

Highlighting the most prominent products and product candidates in its commercial development pipeline, Genetics Institute acknowledges that significant progress has...

ASPIRIN HELPS BAYER IN ITALY

6 April 1992

Favorable trends in drugs business and especially good sales of standard products such as aspirin are reported to have helped...

US HOSPITAL FORMULARY GUIDE

6 April 1992

The American Society of Hospital Pharmacists has released guidelines on formulary system management for its members.

The ASHP notes that in...

US FDA USER FEES: "THE TIME HAS COME"

6 April 1992

People in the US Food and Drug Administration-regulated industries now recognize that the time has arrived for user fees to...

ICN HUBBER GROUP IN SPAIN

6 April 1992

The ICN Hubber Group is investing 1.7 billion pesetas ($2.2 million) in a new pharmaceutical plant near Barcelona in Spain....

NEW DIRECTOR AT WHO

6 April 1992

Lionel Brisson of France has been appointed as director of program development and monitoring in the Office of the Director-General...

BTG SALE COMPLETED

6 April 1992

The sale of British Technology Group by the UK government to a management and employee buy-out consortium was completed at...

AUSTRALIAN LAUNCH OF ROCHE'S AURORIX

6 April 1992

Hoffmann-La Roche's reversible inhibitor of monoamine oxidase type A, Aurorix (moclobemide) has now been launched in Australia. The novel antidepressant...

AMA REPORT ON CONTRACEPTIVES

6 April 1992

The outcome of a report from the American Medical Association's Board of Trustees concludes that long-acting contraceptives may be medically...

ICN-GALENIKA "HEALTHY SHARES"

6 April 1992

Yugoslavia's Tanjug news agency reports that Milan Panic, head of ICN-Galenika and founder of US-based ICN Pharmaceuticals, is saying the...